Compare IPST & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPST | RDHL |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 3.3M |
| IPO Year | 2024 | 2012 |
| Metric | IPST | RDHL |
|---|---|---|
| Price | $2.56 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 249.9K | ★ 819.1K |
| Earning Date | 11-17-2026 | 09-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,402,488.00 | N/A |
| Revenue This Year | $66.82 | $17,592.31 |
| Revenue Next Year | $60.33 | $25.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.41 | N/A |
| 52 Week Low | $0.26 | $0.41 |
| 52 Week High | $308.00 | $1.67 |
| Indicator | IPST | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 40.26 | 34.53 |
| Support Level | $2.18 | N/A |
| Resistance Level | $2.80 | $0.71 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 26.85 | 2.35 |
IP Strategy Holdings Inc operate a diversified business centered on digital asset-based infrastructure and intellectual property (IP) management, supplemented by a legacy craft spirits operating segment. The Company provides public market investors with broad exposure to the around $80 trillion programmable intellectual property economy in a regulated equity format. Its treasury reserve of $IP tokens provides direct participation in the Story ecosystem, which enables on-chain registration, licensing, and monetization of intellectual property.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.